Patent Application
20120095007
The present invention relates to novel carbamoyloxy arylalkan arylpiperazine compound, a pharmaceutical compositions comprising the compound and a method for treating pains including acute pain, chronic pain, neuropathic pain, post-surgery neuropathic pain, diabetic neuropathic pain, postherpetic neuralgia, inflammatory pain, joint pain, migraine headache and the like, anxiety and depression in mammals by administering the compound to the mammals in need of treatment thereof.
Up to now, arylpiperazine compounds were proven to be effective to a variety of indications in the field of central nervous system. In particular, U.S. Pat. No. 3,002,976 reported that the following thiophene-engrafted arylpiperazine compound has a pharmacological effect to treat depression. In this formula, R represents hydrogen, methyl group or halogen.
Also, it has been known that effects of buspirone and its structurally related compounds on the treatment of anxiety is due to their selective activities in serotonin (5-hydroxytryptamine: 5HT) sub-type receptor represented by a receptor 5-HT1A. In particular, U.S. Pat. No. 4,988,814 discloses piperazine derivatives showing affinity to the 5-HT1A receptor characterized as therapeutic agents to treat depression and anxiety.
wherein, R1 is alkyl having carbon atoms of 1 to 6; R2 and R3 are each independently alkyl having carbon atoms of 1 to 6, or R2 and R3 are taken together to form polymethylene having carbon atoms of 2 to 12 or to form a 5-norbornen-2-yl residue with carbon atoms bount to the radicals R2 and R3; X is selected from the group consisting of —CO2—, —OCO—, —OCO2—, —N(R7)CO—, —NHNHCO—, —ON(R7)CO—, —CON(R7)—, —N(R7)CO2—, —OCON(R7)— and —N(R7)CON(R8) (wherein, R7 and R8 are each independently is selected from the group consisting of hydrogen; alkyl having carbon atoms of 1 to 6; phenyl; benzyl; and phenyl or benzyl substituted by halo, alkyl having carbon atoms of 1 to 6, alkoxy having carbon atoms of 1 to 6, cyano, nitro or perhalomethyl); R4 is hydrogen or alkyl having carbon atoms of 1 to 6; R5 is selected from the group consisting of hydrogen; alkyl having carbon atoms of 1 to 8; hydroxyalkyl having carbon atoms of 1 to 3; phenyl; benzyl; and phenyl or benzyl substituted by hydroxy, halo, alkyl having carbon atoms of 1 to 6, alkoxy having carbon atoms of 1 to 6, trifluoromethyl, nitro, cyano, carbalkoxy having carbon atoms of 2 to 7, carboxamido, amino, alkylamino having carbon atoms of 1 to 6 or dialkylamino having carbon atoms of 2 to 12; R6 is phenyl, benzyl, 2-, 3- or 4-pyridinyl, 2-pyrimidinyl or 2-pyrazinyl that may be substituted by at least one substituents selected from the group consisting of hydroxy, halo, alkyl having carbon atoms of 1 to 6, alkoxy having carbon atoms of 1 to 6, trifluoromethyl, nitro, cyano, carbalkoxy having carbon atoms of 2 to 7, carboxamido, amino, alkylamino having carbon atoms of 1 to 6, and dialkylamino having carbon atoms of 2 to 12; n is one integer selected from the group consisting of 0, 1, 2, 3, 4 and 5, provided that R6 is not 2-pyrimidinyl when X is —CON(R7)— (wherein, R7 is alkyl), and R6 is not 3,5-di(trifluoromethyl)phenyl when X is —CO2, R1, R2 and R3 are methyl and n is 1.
The present inventors have confirmed that an arylpiperazine structure is correlated with an effect to treat pains as well as anxiety and depression, conducted comprehensive researches on the arylpiperazine structure, and found that novel carbamoyloxy arylalkan arylpiperazine compounds have a medical effect in various pain-induced animal models. In particular, the present inventors have found that the novel carbamoyloxy arylalkan arylpiperazine compounds show their therpeutic effects to treat a wide scope of pains including acute pain, chronic pain, neuropathic pain, post-surgery neuropathic pain, diabetic neuropathic pain, postherpetic neuralgia, inflammatory pain, joint pain, migraine headache and the like, anxiety and depression. Therefore, the present invention was completed on the basis of the above-mentioned facts.
An aspect of the present invention provides a novel carbamoyloxy arylalkan arylpiperazine derivative compound and pharmaceutically available salts or hydrates thereof.
Another aspect of the present invention provides a pharmaceutical composition for treating pain, anxiety or depression including an effective amount of the compound.
Still another aspect of the present invention provides a method for treating pain, anxiety or depression in mammals by administering an effective amount of the compound to the mammals in need of treatment thereof.
According to an aspect of the present invention, there is provided a carbamoyloxy arylalkan arylpiperazine derivative compound having abundant racemic or enantiomeric characteristics, represented by the following Formula 1, and pharmaceutically available salts or hydrates thereof:
wherein, - - - may selectively form a cyclic ring;
R1 and R2 are hydrogen, or R1 or R2 may be taken together with X1 to form a bicyclic ring;
X1 may phenyl being able to be substituted by at least one identical or different substituent selected from the group consisting of hydrogen, straight or branched alkyl having carbon atoms of 1 to 6, halogen such as F, Cl and Br, straight or branched alkoxy having carbon atoms of 1 to 6, nitro, dimethylamino, and trifluoromethyl; and a bicyclic ring system including naphthyl and methylenedioxyphenyl;
Z is hydrogen or fluorine, or may be taken together with X1 to form a bicyclic ring;
Ar is selected from the group consisting of phenyl, pyridine, pyrimidine which may be substituted by at least one identical or different substituent selected from the group consisting of hydrogen, straight or branched alkyl having carbon atoms of 1 to 6, hydroxy, halogen, straight or branched alkoxy having carbon atoms of 1 to 6, nitro, acetyl, t-butylacetyl, trifluoromethyl, trifluoromethoxy, amino, benzyloxy, 3,4-methylenedioxy, 3,4-ethylenedioxy, pivaloyloxy, ethylcarbonate, phenylcarbonate, carbonic acid benzyl ester, acetate, and cyclopentyloxy; and naphthyl, dihydrobenzodioxinyl, methylenedioxyphenyl, bis(fluorophenyl)methyl and quinoxaline;
Y1 and Y2 are each independently hydrogen or methyl (CH3);
Y3 is hydrogen, phenyl, or carbonyl (═O);
Y4 is hydrogen, or methyl (CH3);
n is integer of 1 or 2;
m is integer of 0 or 1.
According to another aspect of the present invention, there is provided a pharmaceutical composition for treating pain, anxiety or depression including an effective amount of the compound having abundant racemic or enantiomeric characteristics.
According to still another aspect of the present invention, there is provided a method for treating pain, anxiety or depression in mammals by administering to the mammals in need of treatment thereof an effective amount of the compound having abundant racemic or enantiomeric characteristics.
As described above, the novel carbamoyloxy arylalkan arylpiperazine derivative compound, and salts and hydrates thereof according to the present invention may be effectively used as a therapeutic agent for treating pains including acute pain, chronic pain, neuropathic pain, post-surgery neuropathic pain, diabetic pain, postherpetic neuralgia, inflammatory pain, joint pain and migraine headache, anxiety and depression.
Hereinafter, the present invention will be described in more detail.
The present invention is related to a carbamoyloxy arylalkan arylpiperazine derivative compound having abundant racemic or enantiomeric characteristics, represented by the following Formula 1, and pharmaceutically available salts or hydrates thereof:
wherein, - - - may selectively form a cyclic ring;
R1 and R2 are hydrogen, or R1 or R2 may be taken together with X1 to form a bicyclic ring;
X1 may phenyl being able to be substituted by at least one identical or different substituent selected from the group consisting of hydrogen, straight or branched alkyl having carbon atoms of 1 to 6, halogen such as F, Cl and Br, straight or branched alkoxy having carbon atoms of 1 to 6, nitro, dimethylamino, and trifluoromethyl; and a bicyclic ring system including naphthyl and methylenedioxyphenyl;
Z is hydrogen or fluorine, or may be taken together with X1 to form a bicyclic ring;
Ar is selected from the group consisting of phenyl, pyridine, pyrimidine which may be substituted by at least one identical or different substituent selected from the group consisting of hydrogen, straight or branched alkyl having carbon atoms of 1 to 6, hydroxy, halogen, straight or branched alkoxy having carbon atoms of 1 to 6, nitro, acetyl, t-butylacetyl, trifluoromethyl, trifluoromethoxy, amino, benzyloxy, 3,4-methylenedioxy, 3,4-ethylenedioxy, pivaloyloxy, ethylcarbonate, phenylcarbonate, carbonic acid benzyl ester, acetate, and cyclopentyloxy; and naphthyl, dihydrobenzodioxinyl, methylenedioxyphenyl, bis(fluorophenyl)methyl and quinoxaline,
Y1 and Y2 are each independently hydrogen or methyl (CH3);
Y3 is hydrogen, phenyl, or carbonyl (═O);
Y4 is hydrogen, or methyl (CH3);
n is integer of 1 or 2;
m is integer of 0 or 1.
The compounds according to one exemplary embodiment of the present invention may be chemically synthesized as in the following Schemes 1 to 3. However, they are described for the purpose of illustrations only, and the present invention is not particularly limited thereto.
In the following Schemes, HX represents acid that may form pharmaceutically available salts with a compound having basic nitrogen. The acid includes, but is not particularly limited to, for example, hydrochloric aid, sulfuric aid, phosphoric acid, acetic acid, benzoic acid, citric acid, malonic acid, salicylic acid, malic acid, fumaric acid, oxalic acid, succinic acid, tartaric aid, lactic acid, gluconic acid, ascorbic acid, maleic acid, aspartic acid, benzenesulfonic acid, methanesulfonic acid, ethanesulfonic acid, hydroxymethanesulfonic acid, hydroxyethanesulfonic acid, etc. Additional acids may refer to a literature [“Pharmaceutical Salts,” J. Pharm. Sci., 1977; 66(1): 1-19]. The preparation of the compound of the present invention is carried out in a reaction medium that may be illustrated as an ether solvent (tetrahydrofuran, ethylether, propylether, isopropylether, and butylether), an alcohol solvent (methanol, ethanol, and isopropyl alcohol), an ester solvent (ethyl acetate), a halogenated hydrocarbon solvent (dichloromethane, chloroform) and mixtures thereof.
As shown in the Scheme 1, a compound (1-3) was synthesized at the presence of a starting material (1-1) substituted by X1 and phenylpiperazine (1-2) substituted by X2 through a Mannich reaction. A compound (1-4) was prepared by reducing the compound (1-3) with sodium borohydride (NaBH4), reacted with 1,1-carbonyl dimidazole (CDI), and then reacted with various amines (NHR1R2) to obtain a compound (1-5) and its salt (1-6).
The reaction product (1-5) or its salt (1-6) prepared through the Scheme 1 was obtained in the form of a racemic compound.
As shown in the Scheme 2, a compound (2-3) engrafted by various kinds of piperazine derivatives (2-2) was prepared from a starting material '3-chloro-1-phenyl-propan-1-ol (compound (2-1) if n=1) or '4-chloro-1-phenyl-butan-1-ol (compound (2-1) if n=2), reacted with 1,1-carbonyl dimidazole (CDI), and then reacted with amines (NHR1R2) to obtain a compound (2-4) and its salt (2-5).
Stereochemistries of the reaction product (2-4) and its salt (2-5) depend only on the starting material (2-1); that is, the reaction product having an (S)-enantiomer only is obtained from the starting material (2-1) having an (S)-enantiomer, and the reaction product having a (R)-enantiomer only is obtained from the starting material (2-1) having a (R)-enantiomer.
As shown in the Scheme 3, a compound (3-3) was synthesized from phenyl-1-propenylketone (3-1) and substituents-engrafted phenylpiperazine (3-2) through 1,4-Michael addition. The compound (3-3) was subject to the reduction reaction at the presence of sodium borohydride (NaBH4) to obtain a compound (3-4) as an alcohol intermediate, and the compound (3-4) was reacted with 1,1-carbonyl dimidazole (CDI), as described previously above, to obtain a carbamate-engrafted compound (3-5) and its salt (3-6).
The reaction products obtained in the Scheme 3 were all obtained in the form of a racemic compound.
According to the present invention, there is provided a pharmaceutical composition including an effective amount of the compound to treat pain, anxiety or depression. Here, the pharmaceutical composition includes, as an active component, at least one compound among the compounds as listed in this application, and the composition according to the present invention may include any combination of the compounds according to the present invention.
The pharmaceutical composition of present invention may be specifically formulated so that it can be administered via any form, such as suitable routes of administration. Here, the suitable routes of administration may, for example, include oral, rectal, nasal, pulmonary, local, percutaneous, intracisternal, intraperitoneal, vaginal, and parenteral (including subcutaneous, intramuscular, intrathecal, intravenous and transdermal routes) routes. The pharmaceutical composition of present invention is preferably administered via the oral route. The preferred routes of administration will, of course, be varied depending on a variety of factors, including the general conditions and age of the subject being treated, the severity of the conditions being treated, and the selected active components, etc.
Pharmaceutical preparations formulated according to the present invention may be administered orally in any form of administration, such as suitable forms of a tablet, a capsule, a powder, a granule, a pellet, a troche, a dragee, a pill or lozenge, a solution or suspension in an aqueous or non-aqueous liquid, or an oil-in-water or water-in-oil liquid emulsion, an elixir, a syrup, etc., or be administered parenterally in the form of injections. Other pharmaceutical compositions that may be administered parenterally include a dispersion, a suspension and an emulsion, as well as sterile powders included in a sterile injection solution or dispersion before their use. It is considered that a depot injection formulation is also included within the scope of the present invention. Other suitable forms of administration include a suppository, a spray, an ointment, a cream, a gelatin, an inhalant, a skin patch, etc. The composition according to the present invention may be formulated according to various methods known in the art. Also, pharmaceutically available carrier, diluent, excipient or other additives, which are used in general in the art, may be used herein.
The carrier is that which generally used in formulations, and includes, but is not particularly limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methyl hydroxybenzoate, propyl hydroxy benzoate, talc, magnesium stearate, mineral oil, etc. The composition of the present invention may further includes a preservative, a stability-improving compound, a viscosity-improving/regulating compound, a solubility-improving compound, a sweetener, a dye, a taste-enhancing compound, an osmosis-inducing salt, a buffer, an antioxidant, etc.
Where the above-mentioned compounds show a desired effect to treat pain, anxiety or depression, the compounds may be used in the form of solvates, esters, stereoisomers, etc. including free compounds, pharmaceutically available salts and hydrates. Also, the above-mentioned compounds are all included in the scope of the present invention.
According to the present invention, the pharmaceutically available salts may include pharmaceutically available acid addition salts. The pharmaceutically available acid addition salts may be obtained from inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydriodic acid, nitrous acid and phosphorous acid; and non-toxic organic acids such as aliphatic mono and dicarboxylate, phenyl-substituted alkanoate, hydroxy alkanoate and alkandioate, aromatic acids, aliphatic and aromatic sulfonic acids; and the like. Specific examples of the pharmaceutically available salts includes, but is not particularly limited to, sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate chloride, bromide, iodide, fluoride, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propionate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexane-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, terephthalate, benzenesulfonate, toluenesulfonate, chlorobenzenesulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, β-hydroxybutyrate, glycolate, maleate, tartrate, methane sulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate and mandelate. Particularly, hydrochloric acid and methane sulfonate are preferred.
The present invention provides a method for treating pain, anxiety or depression in mammals, characterized in that an effective amount of the compound is administered to the mammals in need of treatment thereof.
The pain, which may be treated by the compound of the present invention, includes a wide range of pains such as acute pain, chronic pain, neuropathic pain, post-surgery neuropathic pain, diabetic pain, postherpetic neuralgia, inflammatory pain, joint pain, migraine headache, etc.
In general, the pharmaceutical composition of the present invention is administered as with active component at a unit dose ranging from approximately 20 to 500 mg. The total daily dose may be generally administered at the amount ranging from approximately 10 to 7000 mg, and preferably from 20 to 3500 mg of the active compound of the present invention. However, the active compound may also be administered at a certain amount out of the dose range under general investigation of the conditions of patients, and also in consideration of the activity of agents to be administered. In this case, the optimum dose amount of such agents in the particular conditions should be determined by routine experimentations.
The compound of the present invention may be administered in single or multiple daily doses, and the dose of the compound may be preferably divided into one, two and three times per day. The compound of the present invention may be administered alone or in combination of a pharmaceutically available carrier or an excipient. The pharmaceutical composition according to the present invention may be formulated in a pharmaceutically available carrier or a diluent, as well as in a supplement and an excipient that are widely known in the art. For convenience sake, the formulations may be present in dosages suitable for such administration by using the methods known in the field of pharmacology.
Hereinafter, exemplary embodiments of the present invention will be described in detail. However, it should be understood that the description proposed herein is just a preferable example for the purpose of illustrations only, not intended to limit the scope of the invention.
1. Synthesis of Carbamoyloxy Arylalkan Arylpiperazine Compound
Acetophenone (4.67 mmol) and phenylpiperazine (5.61 mmol) were dissolved in ethanol (30 mL), and the resulting mixture was adjusted to pH 2 to 3 by adding concentrated hydrochloric acid dropwise. Paraformaldehyde (46.7 mmol) was added to the mixture, and the resulting mixture was refluxed for 24 hours. The resulting reaction mixture were distilled under a reduced pressure, neutralized with 1 normal sodium chloride aqueous solution, diluted with water, and then extracted several times with ethylacetate. The resulting organic phase was dried over magnesium sulfate, and filtered, and the resulting filtrate was concentrated under a reduced pressure, and separated and purified with column chromatography (hexane:ethyl acetate=1:1 to 1:10). The separated compound (3.5 mmol) was dissolved in methanol (20 mL), and cooled to 0° C., and sodium borohydride (5 mmol) was added slowly to the mixture. The resulting mixture was stirred at a room temperature for 2 hours, and concentrated under a reduced pressure. Then, the resulting yellow pellet was purified with column chromatography (hexane:ethylacetate=1:1) to obtain an alcohol intermediate. The prepared intermediate (10 mmol) was dissolved in tetrahydrofuran (15 mL), and 1,1′-carbonyldiimidazole (20 mmol) was added to the intermediate mixture. The resulting intermediate mixture was stirred at a room temperature for 1 hour, and excessive ammonium hydroxide was added to the intermediate mixture, and the resulting mixture was stirred at a room temperature for additional 2 hours. The resulting reaction mixture was diluted with water, and extracted several times with ethyl acetate to obtain an organic phase. The prepared organic phase was dried over magnesium sulfate, and concentrated under a reduced pressure. The resulting pellet was purified with column chromatography (hexane:ethyl acetate=1:1 to hexane:ethylacetate=0:1) to obtain a title compound.
1H NMR (200 MHz, CDCl3) d: 1.98 (m, 1H), 2.21 (m, 1H), 2.41 (m, 2H), 2.60 (m, 4H), 3.10 (m, 4H), 4.92 (br, 2H), 5.75 (t, 1H), 6.89 (m, 4H), 7.11 (m, 5H)
Compounds of Examples 2 to 84 were prepared in the same manner as in the Example 1, except that the different starting materials were used in the Examples 2 to 84.
A title compound was prepared in the same manner as in Example 1 except for the use of 4′-chloroacetophenone and phenylpiperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 1.99 (m, 1H), 2.16 (m, 1H), 2.33 (m, 2H), 2.45 (m, 4H), 3.01 (m, 4H), 4.57 (br, 2H), 5.51 (t, 1H), 6.80 (m, 2H), 7.19 (m, 2H), 7.28 (m, 5H)
A title compound was prepared in the same manner as in Example 1 except for the use of 4′-dimethylaminoacetophenone and phenylpiperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.62 (m, 3H), 2.71 (m, 1H), 2.82 (m, 2H), 2.94 (dd, 6H), 3.25 (m, 4H), 4.87 (dd, 1H), 5.8 (br, 2H), 6.71 (d, 2H), 6.9 (m, 3H), 7.26 (m, 5H)
A title compound was prepared in the same manner as in Example 1 except for the use of 3′-nitroaminoacetophenone and phenylpiperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.58 (m, 2H), 2.66 (m, 2H), 2.95 (m, 4H), 3.36 (m, 4H), 4.86 (br, 2H), 5.80 (t, 1H), 6.89-6.97 (m, 3H), 7.29 (m, 2H), 7.54 (t, 1H), 7.75 (d, 1H), 8.15 (q, 1H), 8.29 (d, 1H)
A title compound was prepared in the same manner as in Example 1 except for the use of 4′-tert-butylacetophenone and phenylpiperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 1.32 (s, 9H), 3.27 (m, 6H), 3.41 (m, 4H), 3.88 (m, 4H), 4.90 (br, 2H), 5.66 (t, 1H), 6.81 (m, 1H), 7.01 (m, 3H), 7.42 (m, 5H)
A title compound was prepared in the same manner as in Example 1 except for the use of 4′-fluoroacetophenone and phenylpiperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 1.88 (m, 2H), 2.76 (m, 6H), 3.27 (m, 2H), 4.57 (br, 2H), 5.51 (t, 1H), 6.89 (m, 4H), 7.32 (m, 5H)
A title compound was prepared in the same manner as in Example 1 except for the use of 3′-chloroacetophenone and phenylpiperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 1.85 (m, 2H), 2.61-2.84 (m, 6H), 3.27 (m, 4H), 4.83 (br, 2H), 5.79 (t, 1H), 6.89 (m, 3H), 7.21-7.40 (m, 6H)
A title compound was prepared in the same manner as in Example 1 except for the use of 4′-methoxyacetophenone and phenylpiperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.56 (m, 2H), 2.65 (m, 4H), 2.93 (m, 2H), 3.25 (m, 4H), 3.81 (s, 3H), 4.77 (t, 1H), 5.02 (br, 2H), 6.91 (m, 5H), 7.29 (m, 4H)
A title compound was prepared in the same manner as in Example 1 except for the use of 4′-nitroacetophenone and phenylpiperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.22 (m, 2H), 3.23 (m, 6H), 3.68 (m, 2H), 3.91 (m, 2H), 5.10 (br, 2H), 5.81 (t, 1H), 6.91 (m, 2H), 7.02 (m, 2H), 7.40 (m, 2H), 7.62 (m, 2H), 8.23 (m, 2H)
A title compound was prepared in the same manner as in Example 1 except for the use of 4′-methylacetophenone and phenylpiperazine as starting materials.
1H NMR (500 MHz, DMSO) d: 2.11 (s, 1H), 2.31 (s, 3H), 2.50 (s, 1H), 3.20 (m, 6H), 3.51 (m, 2H), 5.55 (t, 1H), 6.80 (br, 2H), 6.89 (m, 1H), 7.01 (m, 2H), 7.24 (m, 4H), 7.29 (m, 4H)
A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 1-(2,3-dihydro-benzo[1,4]dioxin-6-yl-1)-piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.03 (m, 1H), 2.21 (m, 1H), 2.42 (m, 2H), 2.55 (m, 4H), 3.05 (m, 4H), 4.20 (m, 4H), 4.80 (br, 2H), 5.82 (t, 1H), 6.45 (m, 2H), 6.84 (m, 1H), 7.32 (m, 5H)
A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 4-trifluoromethoxy-phenylpiperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.12 (m, 2H), 2.41 (m, 2H), 2.56 (m, 4H), 3.17 (m, 4H), 4.65 (br, 2H), 5.90 (t, 1H), 6.86 (m, 2H), 7.11 (m, 2H), 7.31 (m, 5H)
A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2,4-dimethyl-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 1.97-2.10 (m, 1H), 2.13-2.24 (m, 1H), 2.29 (s, 3H), 2.30 (s, 3H), 2.43-2.51 (m, 2H), 2.61-2.82 (m, 4H), 2.91-2.95 (m, 4H), 4.84 (br, 2H), 5.76 (t, 1H), 6.94-7.03 (m, 3H), 7.28-7.38 (m, 5H)
A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2-trifluoromethyl-phenyl piperazine as starting materials.
1H NMR (200 MHz, Acetone) d: 2.07 (m, 2H), 2.35 (m, 2H), 2.45 (m, 4H), 2.76 (m, 4H), 5.78 (t, 1H), 6.01 (br, 2H), 7.34 (m, 5H), 7.57 (m, 4H)
A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2-chloro-phenyl piperazine as starting materials.
1H NMR (200 MHz, Acetone) d: 1.99 (m, 2H), 2.21 (m, 2H), 2.36 (m, 4H), 2.77 (m, 4H), 5.89 (t, 1H), 6.10 (br, 2H), 7.30 (m, 5H), 7.48 (m, 4H)
A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 4-nitrophenyl-piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.11 (m, 2H), 2.26 (m, 2H), 2.51 (m, 4H), 2.59 (m, 4H), 4.81 (br, 2H), 5.81 (t, 1H), 6.48 (m, 4H), 7.28 (2H), 7.42 (m, 2H)
A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2,4-dimethoxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.06 (m, 1H), 2.18 (m, 1H), 2.45 (m, 3H), 2.64 (m, 4H), 3.03 (m, 4H), 3.79 (s, 3H), 3.84 (s, 3H), 3.84 (s, 3H), 4.73 (br, 2H), 5.87 (t, 1H), 6.48 (m, 2H), 6.86 (d, 1H), 7.28-7.37 (m, 5H)
A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 3-trifluoromethyl-4-chlorophenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.03 (m, 1H), 2.18 (m, 1H), 2.44 (m, 2H), 2.60 (m, 4H), 3.23 (m, 4H), 4.71 (br, 2H), 5.78 (t, 1H), 6.96 (m, 1H), 7.28-7.32 (m, 7H)
A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2,6-dimethyl-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.05 (m, 1H), 2.18 (m, 1H), 2.27 (s, 6H), 2.41 (m, 2H), 2.55 (m, 4H), 3.13 (m, 4H), 4.70 (br, 2H), 5.77 (t, 1H), 6.97-6.99 (m, 3H), 7.28-7.39 (m, 5H)
A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 4-methoxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.12 (m, 1H), 2.27 (m, 1H), 2.42 (m, 2H), 2.65 (m, 4H), 3.13 (m, 4H), 3.79 (s, 3H), 4.87 (br, 2H), 5.79 (t, 1H), 6.89 (m, 4H), 7.33 (m, 5H)
A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 4-fluoro-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.11 (m, 1H), 2.21 (m, 1H), 2.29 (m, 2H), 2.61 (m, 4H), 3.14 (m, 4H), 4.83 (br, 2H), 5.75 (t, 1H), 6.93 (m, 4H), 7.33 (m, 5H)
A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 4-chloro-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 1.98 (m, 1H), 2.21 (m, 1H), 2.43 (m, 2H), 2.60 (m, 4H), 3.18 (m, 4H), 4.67 (br, 2H), 5.76 (t, 1H), 6.85 (m, 2H), 7.24 (m, 2H), 7.37 (m, 5H)
A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2-hydroxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.05 (m, 2H), 2.40 (m, 2H), 2.62 (m, 4H), 2.90 (m, 4H), 4.63 (br, 2H), 5.71 (t, 1H), 6.96 (m, 3H), 7.14 (m, 2H), 7.35 (m, 3H)
A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 3-methyl-phenyl piperazine as starting materials.
1H NMR (200 MHz, Acetone) d: 2.07 (m, 2H), 2.28 (s, 3H), 2.39 (m, 2H), 2.55 (m, 4H), 3.17 (m, 4H), 5.81 (t, 1H), 6.61 (br, 2H), 6.78 (m, 2H), 7.10 (t, 1H), 7.31-7.40 (m, 5H)
A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2-pyridylpiperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.19 (m, 2H), 2.32 (m, 2H), 2.48 (m, 4H), 2.67 (m, 4H), 4.84 (br, 2H), 5.79 (t, 1H), 6.89 (m, 1H), 7.19 (m, 1H), 7.34 (m, 3H), 7.56 (m, 3H), 8.11 (m, 1H)
A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 3-methoxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d 1.97 (m, 2H), 2.39 (m, 2H), 2.55 (m, 4H), 3.18 (m, 4H), 3.77 (s, 3H), 5.76 (t, 1H), 6.1 (br, 2H), 6.43 (m, 1H), 6.53 (m, 1H), 7.12 (t, 1H), 7.30-7.43 (m, 5H)
A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2-methoxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 1.88 (m, 2H), 2.29 (m, 2H), 2.46 (m, 4H), 3.09 (m, 4H), 3.82 (s, 3H), 5.66 (t, 1H), 5.90 (br, 2H), 6.82 (m, 4H), 7.29 (m, 5H)
A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 1-(β-chloro-pyridin-2-yl)-piperazine as starting materials.
1H NMR (200 MHz, Acetone) d: 1.58 (m, 2H), 1.89 (m, 2H), 2.42 (m, 2H), 2.54 (m, 4H), 3.32 (m, 4H), 5.69 (t, 1H), 6.07 (br, 2H), 6.95 (m, 1H), 7.27-7.39 (m, 5H), 7.71 (m, 1H), 8.21 (m, 1H)
A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 3,4-dimethyl-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.01 (m, 2H), 2.17 (s, 3H), 2.21 (s, 3H), 2.40 (m, 2H), 2.57 (m, 4H), 3.13 (m, 4H), 4.78 (br, 2H), 5.82 (t, 1H), 6.82 (m, 2H), 7.01 (m, 1H), 7.33 (m, 5H)
A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 3,4-methylene dioxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 1.99 (m, 1H), 2.12 (m, 1H), 2.36 (m, 2H), 2.54 (m, 4H), 3.05 (m, 4H), 4.77 (br, 2H), 5.72 (t, 1H), 5.90 (s, 2H), 6.32 (dd, 1H), 6.55 (m, 1H), 6.72 (d, 1H), 7.33 (m, 5H)
A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 3,4-dichloro-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.10 (m, 2H), 2.39 (m, 2H), 2.54 (m, 4H), 3.15 (m, 4H), 4.62 (br, 2H), 5.85 (t, 1H), 6.81 (dd, 1H), 6.99 (m, 1H), 7.34 (m, 6H)
A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 5-chloro-2-methoxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.04 (m, 2H), 2.41 (m, 2H), 2.61 (m, 4H), 3.06 (m, 4H), 3.82 (s, 3H), 4.62 (br, 2H), 5.82 (t, 1H), 6.71 (d, 1H), 6.99 (m, 2H), 7.34 (m, 5H)
A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 3,5-dimethoxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 1.99 (m, 2H), 2.21 (m, 1H), 2.49 (m, 2H), 2.58 (m, 4H), 3.20 (m, 4H), 3.80 (s, 3H), 4.89 (br, 2H), 5.89 (t, 1H), 6.11 (m, 1H), 6.12 (m, 2H), 7.37 (m, 5H)
A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2-piperazin-1-yl-pyrimidine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.00 (m, 2H), 2.44 (m, 6H), 3.83 (m, 4H), 4.79 (br, 2H), 5.45 (t, 1H), 6.49 (t, 1H), 7.31 (m, 5H), 8.31 (m, 2H)
A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2-nitro-4-trifluoromethyl-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.10 (m, 2H), 2.21 (m, 2H), 2.59 (m, 4H), 3.19 (m, 4H), 4.62 (br, 2H), 5.81 (t, 1H), 7.36 (m, 5H), 7.41 (m, 1H), 7.62 (m, 1H), 8.09 (s, 1H)
A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 3-chloro-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.11 (m, 1H), 2.21 (m, 1H), 2.29 (m, 2H), 2.61 (m, 4H), 3.14 (m, 4H), 4.83 (br, 2H), 5.75 (t, 1H), 6.93 (m, 4H), 7.33 (m, 5H)
A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2-methyl-phenyl piperazine as starting materials.
1H NMR (200 MHz, Acetone) d: 2.05 (m, 2H), 2.19 (s, 3H), 2.37 (m, 2H), 2.58 (m, 4H), 2.89 (m, 4H), 5.78 (t, 1H), 6.2 (br, 2H), 6.92 (t, 1H), 7.19 (m, 3H), 7.31-7.40 (m, 5H)
A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 4-methyl-phenyl piperazine as starting materials.
1H NMR (200 MHz, Acetone) d: 2.08 (m, 2H), 2.10 (s, 3H), 2.29 (m, 2H), 2.55 (m, 4H), 3.13 (m, 4H), 5.76 (t, 1H), 6.01 (br, 2H), 6.85 (m, 2H), 7.03 (m, 5H), 7.31-7.40 (m, 5H)
A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 3-trifluoromethyl-phenyl piperazine as starting materials.
1H NMR (200 MHz, Acetone) d: 2.03 (m, 2H), 2.42 (m, 2H), 2.58 (m, 4H), 3.29 (m, 4H), 5.78 (t, 1H), 6.01 (br, 2H), 7.09 (m, 1H), 7.23 (m, 2H), 7.30-7.43 (m, 6H)
A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 4-trifluoromethyl-phenyl piperazine as starting materials.
1H NMR (200 MHz, Acetone) d: 2.41 (m, 2H), 2.57 (m, 4H), 2.83 (m, 2H), 3.34 (m, 4H), 5.77 (t, 1H), 5.97 (br, 2H), 7.09 (m, 2H), 7.36 (m, 5H), 7.52 (m, 2H)
A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2-fluoro-phenyl piperazine as starting materials.
1H NMR (200 MHz, Acetone) d: 2.05 (m, 2H), 2.38 (m, 2H), 2.58 (m, 4H), 3.09 (m, 4H), 5.77 (t, 1H), 5.89 (br, 2H), 7.06 (m, 4H), 7.30-7.40 (m, 5H)
A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 3-fluoro-phenyl piperazine as starting materials.
1H NMR (200 MHz, Acetone) d: 2.08 (m, 2H), 2.39 (m, 2H), 2.56 (m, 4H), 3.22 (m, 4H), 5.80 (t, 1H), 6.17 (br, 2H), 6.62 (m, 1H), 6.78 (m, 2H), 7.20-7.45 (m, 6H)
A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 2-nitro-phenyl piperazine as starting materials.
1H NMR (200 MHz, Acetone) d: 2.05 (m, 2H), 2.40 (m, 2H), 2.44-2.62 (m, 4H), 3.07 (m, 4H), 5.77 (t, 1H), 5.98 (br, 2H), 7.32 (m, 1H), 7.57-7.76 (m, 2H)
A title compound was prepared in the same manner as in Example 1 except for the use of 4′-nitro acetophenone and 4-methoxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 1.95 (m, 1H), 2.17 (m, 1H), 2.43 (m, 2H), 2.60 (m, 4H), 3.10 (m, 4H), 3.78 (s, 3H), 4.91 (br, 2H), 5.83 (t, 1H), 6.88 (m, 4H), 7.53 (d, 2H), 8.23 (d, 2H)
A title compound was prepared in the same manner as in Example 1 except for the use of 3′-chloro acetophenone and 4-methoxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 1.98 (m, 1H), 2.20 (m, 1H), 2.43 (m, 2H), 2.61 (m, 4H), 3.11 (m, 4H), 3.79 (s, 3H), 4.75 (br, 2H), 5.73 (t, 1H), 6.89 (m, 4H), 7.32 (m, 4H)
A title compound was prepared in the same manner as in Example 1 except for the use of 2′-fluoro acetophenone and 4-methoxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 1.88-2.00 (m, 2H), 2.32 (m, 2H), 2.58 (m, 4H), 3.09 (m, 4H), 3.81 (s, 3H), 4.89 (br, 2H), 5.81 (t, 1H), 6.92 (m, 4H), 7.28 (m, 5H)
A title compound was prepared in the same manner as in Example 1 except for the use of 4′-methoxy acetophenone and 4-methoxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 1.97 (m, 1H), 2.17 (m, 1H), 2.41 (m, 2H), 2.60 (m, 4H), 3.10 (m, 4H), 3.78 (s, 3H), 3.81 (s, 3H), 4.87 (br, 2H), 5.69 (t, 1H), 6.88 (m, 6H), 7.30 (m, 2H)
A title compound was prepared in the same manner as in Example 1 except for the use of 4′-tert-butyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 1.32 (s, 9H), 1.94 (m, 2H), 2.68 (m, 3H), 2.80 (m, 3H), 3.27 (m, 4H), 3.78 (s, 3H), 4.95 (t, 1H), 5.82 (br, 2H), 6.90 (m, 3H), 7.24-7.38 (m, 6H)
A title compound was prepared in the same manner as in Example 1 except for the use of 2′-acetonaphthone and 4-methoxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.08 (m, 1H), 2.43 (m, 1H), 2.47 (m, 2H), 2.55 (m, 4H), 3.12 (m, 4H), 3.79 (s, 3H), 4.7 (br, 2H), 5.93 (t, 1H), 6.89 (m, 4H), 7.51 (m, 3H), 7.86 (m, 4H)
A title compound was prepared in the same manner as in Example 1 except for the use of 2′-chloroacetophenone and 4-methoxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.08 (m, 2H), 2.58 (m, 5H), 3.10 (m, 4H), 3.78 (s, 3H), 4.85 (br, 2H), 6.12 (t, 1H), 6.82-6.94 (m, 4H), 7.21-7.45 (m, 4H)
A title compound was prepared in the same manner as in Example 1 except for the use of 2′-trifluoromethyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.04 (m, 2H), 2.63 (m, 6H), 3.11 (m, 4H), 3.79 (s, 3H), 4.78 (br, 2H), 6.12 (t, 1H), 6.83-6.95 (m, 4H), 7.37-7.69 (m, 4H)
A title compound was prepared in the same manner as in Example 1 except for the use of 3′,4′-difluoromethyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 1.98 (m, 1H), 2.21 (m, 1H), 2.41 (m, 2H), 2.60 (m, 4H), 3.10 (m, 4H), 3.80 (s, 3H), 4.92 (br, 2H), 5.75 (t, 1H), 6.89 (m, 4H), 7.11 (m, 3H)
A title compound was prepared in the same manner as in Example 1 except for the use of 3′-fluoro acetophenone and 4-methoxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 1.99 (m, 1H), 2.19 (m, 1H), 2.43 (m, 2H), 2.60 (m, 4H), 3.11 (m, 4H), 3.78 (s, 3H), 4.88 (br, 2H), 5.74 (t, 1H), 6.91 (m, 4H), 7.10 (m, 3H), 7.33 (m, 1H)
A title compound was prepared in the same manner as in Example 1 except for the use of 3′-methoxy acetophenone and 4-methoxy-phenyl piperazine as starting material s.
1H NMR (200 MHz, CDCl3) d: 1.98 (m, 1H), 2.14 (m, 1H), 2.44 (m, 2H), 2.61 (m, 4H), 3.11 (m, 4H), 3.78 (s, 3H), 3.82 (s, 3H), 4.86 (br, 2H), 5.72 (t, 1H), 6.83 (m, 7H), 7.28 (m, 1H)
A title compound was prepared in the same manner as in Example 1 except for the use of 1′-acetonaphthone and 4-methoxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.26 (m, 2H), 2.55 (m, 2H), 2.63 (m, 4H), 3.12 (m, 4H), 3.80 (s, 3H), 4.71 (br, 2H), 6.59 (t, 1H), 6.92 (m, 4H), 7.45-7.58 (m, 4H), 7.62-7.92 (m, 2H), 8.25 (d, 1H)
A title compound was prepared in the same manner as in Example 1 except for the use of 4′-methyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.17 (m, 2H), 2.36 (s, 3H), 2.42 (m, 2H), 2.64 (m, 4H), 3.12 (m, 4H), 3.78 (s, 3H), 4.78 (br, 2H), 5.87 (t, 1H), 6.88 (m, 4H), 7.23 (m, 4H)
A title compound was prepared in the same manner as in Example 1 except for the use of 3′-methyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.01 (m, 1H), 2.178 (m, 1H), 2.37 (s, 3H), 2.42 (m, 2H), 2.61 (m, 4H), 3.11 (m, 4H), 3.79 (s, 3H), 4.86 (br, 2H), 5.72 (t, 1), 6.89 (m, 4H), 7.18 (m, 4H)
A title compound was prepared in the same manner as in Example 1 except for the use of 2′,4′-dichloroacetophenone and 4-methoxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.06 (m, 2H), 2.50 (m, 2H), 2.6 (m, 2H), 3.1 (m, 4H), 3.78 (s, 3H), 4.76 (br, 2H), 6.07 (t, 1H), 6.88 (m, 4H), 7.32 (m, 3H)
A title compound was prepared in the same manner as in Example 1 except for the use of 2′-methyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 1.95-2.03 (m, 1H), 2.06-2.13 (m, 1H), 2.45 (s, 3H), 2.5-2.63 (m, 4H), 3.08-3.13 (m, 4H), 3.79 (s, 3H), 4.66 (br, 2H), 6.00 (t, 1H), 6.83-6.95 (m, 4H), 7.18-7.40 (m, 4H)
A title compound was prepared in the same manner as in Example 1 except for the use of 2′,4′-dimethyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 1.94-2.04 (m, 2H), 2.10-2.21 (m, 2H), 2.32 (s, 3H), 2.41 (s, 3H), 2.60-2.63 (m, 4H), 3.08-3.13 (m, 4H), 3.79 (s, 3H), 4.65 (br, 2H), 5.96 (t, 1H), 6.87-7.06 (m, 6H), 7.27 (d, 1H)
A title compound was prepared in the same manner as in Example 1 except for the use of 3′,4′-dimethyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.01 (m, 1H), 2.11 (m, 1H), 2.32 (s, 3H), 2.41 (s, 3H), 2.44 (m, 2H), 2.62 (m, 4H), 3.12 (m, 4H), 3.80 (s, 3H), 4.65 (br, 2H), 5.69 (t, 1H), 6.91 (m, 4H), 7.14 (m, 3H)
A title compound was prepared in the same manner as in Example 1 except for the use of 2′,5′-dimethyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 1.99 (m, 2H), 2.09 (m, 2H), 2.54 (m, 3H), 3.10 (m, 4H), 3.80 (s, 3H), 4.75 (br, 2H), 5.96 (t, 1H), 6.88 (m, 4H), 7.03 (dd, 2H), 7.18 (s, 1H)
A title compound was prepared in the same manner as in Example 1 except for the use of 4′-chloro-3′-trifluoromethyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 1.93 (m, 1H), 2.22 (m, 1H), 2.39 (m, 2H), 2.63 (m, 4H), 3.11 (m, 4H), 3.79 (s, 3H), 4.89 (br, 2H), 5.77 (t, 1H), 6.89 (m, 4H), 7.52 (m, 4H)
A title compound was prepared in the same manner as in Example 1 except for the use of 2′-nitroacetophenone and 4-methoxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.07 (m, 2H), 2.62 (m, 6H), 3.09 (m, 4H), 3.78 (s, 3H), 4.80 (br, 2H), 6.27 (t, 1H), 6.88 (m, 4H), 7.45 (m, 1H), 7.64 (d, 2H), 7.98 (d, 1H)
A title compound was prepared in the same manner as in Example 1 except for the use of 3′-nitroacetophenone and 4-methoxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 1.98 (m, 2H), 2.42-2.65 (m, 6H), 3.11 (m, 4H), 3.80 (s, 3H), 5.01 (br, 2H), 6.22 (t, 1H), 6.78 (m, 4H), 7.37 (m, 1H), 7.8 (d, 2H), 7.98 (d, 1H)
A title compound was prepared in the same manner as in Example 1 except for the use of 4′-trifluoromethyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 1.97 (m, 1H), 2.20 (m, 1H), 2.44 (m, 2H), 2.61 (m, 4H), 3.15 (m, 4H), 3.79 (s, 3H), 4.73 (br, 2H), 5.80 (t, 1H), 6.89 (m, 4H), 7.42 (d, 2H), 7.64 (d, 2H)
A title compound was prepared in the same manner as in Example 1 except for the use of 3′,4′-methylenedioxy acetophenone and 4-methoxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 1.19 (m, 1H), 2.19 (m, 1H), 2.39 (m, 2H), 2.60 (m, 4H), 3.11 (m, 4H), 3.78 (s, 3H), 4.75 (br, 2H), 5.65 (t, 1H), 5.97 (s, 2H), 6.76-6.94 (m, 7H)
A title compound was prepared in the same manner as in Example 1 except for the use of 3′-trifluoromethyl acetophenone and 4-methoxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 1.99 (m, 1H), 2.22 (m, 1H), 2.39 (m, 2H), 2.61 (m, 4H), 3.11 (m, 4H), 3.79 (s, 3H), 4.77 (br, 2H) 5.82 (t, 1H), 6.89 (m, 4H), 7.56 (m, 4H)
A title compound was prepared in the same manner as in Example 1 except for the use of 2′-fluoroacetophenone and 4-methoxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.14 (m, 2H), 2.49 (m, 2H), 2.61 (m, 4H), 3.09 (m, 4H), 3.79 (s, 3H), 4.91 (br, 2H), 6.02 (t, 1H), 6.91 (m, 4H), 7.14 (m, 2H), 7.36 (m, 2H)
A title compound was prepared in the same manner as in Example 1 except for the use of 3′,4′-dichloro acetophenone and 4-methoxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.11 (m, 2H), 2.17 (m, 2H), 2.68 (m, 4H), 3.15 (m, 4H), 3.72 (s, 3H), 4.81 (br, 2H), 5.90 (t, 1H), 6.92 (m, 4H), 7.12 (m, 1H), 7.28 (m, 2H)
A title compound was prepared in the same manner as in Example 1 except for the use of 4′-dichloro acetophenone and 4-methoxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 1.98 (m, 1H), 2.17 (m, 1H), 2.42 (m, 2H), 2.61 (m, 4H), 3.11 (m, 4H), 3.80 (s, 3H), 4.83 (br, 2H), 5.87 (t, 1H), 6.89 (m, 4H), 7.32 (m, 4H)
A title compound was prepared in the same manner as in Example 1 except for the use of 4′-chloro-3′-trifluoromethyl acetophenone and 4-hydroxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.01 (m, 1H), 2.21 (m, 1H), 2.53 (m, 2H), 2.71 (m, 4H), 4.92 (br, 2H), 5.82 (t, 1H), 6.80 (m, 4H), 7.49 (m, 2H), 7.70 (s, 1H)
A title compound was prepared in the same manner as in Example 1 except for the use of 3′,4′-dichloroacetophenone and 4-hydroxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.08 (m, 2H), 2.16 (m, 2H), 2.65 (m, 4H), 3.11 (m, 4H), 4.75 (br, 2H), 5.83 (t, 1H), 6.82 (m, 4H), 7.29 (m, 1H), 7.43 (m, 2H)
A title compound was prepared in the same manner as in Example 1 except for the use of 4′-fluoro acetophenone and 2-ethoxy-phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 1.43 (m, 3H), 2.18 (m, 2H), 2.55-3.05 (m, 10H), 4.11 (m, 2H), 5.76 (t, 1H), 5.99 (br, 2H), 7.08 (m, 3H), 7.13 (m, 3H), 7.44 (m, 2H)
A title compound was prepared in the same manner as in Example 1 except for the use of 4′-fluoro acetophenone and 5-chloro-2-methoxy phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.38 (m, 2H), 2.54 (m, 6H), 3.04 (m, 4H), 3.86 (s, 3H), 5.73 (t, 1H), 5.93 (br, 2H), 6.93 (m, 4H), 7.16 (m, 2H), 7.51 (m, 1H)
A title compound was prepared in the same manner as in Example 1 except for the use of 4′-fluoro acetophenone and 3,4-dichloro phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.22 (m, 1H), 2.48 (m, 3H), 2.54 (m, 6H), 3.24 (m, 2H), 5.72 (t, 1H), 5.97 (br, 2H), 6.91 (m, 1H), 7.08 (m, 3H), 7.45 (m, 3H)
A title compound was prepared in the same manner as in Example 1 except for the use of 4′-fluoro acetophenone and 4-methoxy phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 1.89 (m, 1H), 2.15 (m, 1H), 2.42 (m, 2H), 2.58 (m, 4H), 3.07 (m, 4H), 3.76 (s, 3H), 4.93 (br, 2H), 5.82 (t, 1H), 6.86 (m, 4H), 7.02 (m, 2H), 7.39 (m, 2H)
A title compound was prepared in the same manner as in Example 1 except for the use of 4′-fluoro acetophenone and 2-methoxy phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 1.99 (m, 1H), 2.20 (m, 1H), 2.43 (m, 2H), 2.97 (m, 4H), 3.11 (m, 4H), 3.87 (s, 3H), 4.62 (br, 2H), 5.87 (t, 1H), 6.89-7.09 (m, 6H), 7.35 (m, 2H)
A title compound was prepared in the same manner as in Example 1 except for the use of 4′-fluoro acetophenone and 4-nitro phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.07 (m, 1H), 2.17 (m, 1H), 2.65 (m, 4H), 3.49 (m, 4H), 4.65 (br, 2H), 5.75 (t, 1H), 6.83 (m, 2H), 6.98 (m, 2H), 7.35 (m, 2H), 8.18 (m, 2H)
A title compound was prepared in the same manner as in Example 1 except for the use of 4′-fluoro acetophenone and 2-methyl phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.01 (m, 2H), 2.17 (m, 2H), 2.31 (s, 3H), 2.43 (m, 2H), 2.63 (m, 4H), 2.69 (m, 4H), 4.77 (br, 2H), 5.76 (t, 1H), 7.09 (m, 4H), 7.23 (m, 2H), 7.36 (m, 3H)
A title compound was prepared in the same manner as in Example 1 except for the use of 4′-fluoro acetophenone and 4-fluoro phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 1.89 (m, 1H), 2.21 (m, 1H), 2.39 (m, 2H), 2.59 (m, 4H), 3.14 (m, 4H), 4.82 (br, 2H), 5.80 (t, 1H), 6.89-7.09 (m, 5H), 7.24 (m, 3H)
A title compound was prepared in the same manner as in Example 1 except for the use of α-tetralone and 4-methoxy phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 1.91 (m, 3H), 2.52 (m, 2H), 2.67 (m, 4H), 2.80 (m, 2H), 3.15 (m, 4H), 3.78 (s, 3H), 4.66 (br, 2H), 6.05 (t, 1H), 6.90 (m, 4H), 7.28 (m, 4H)
A title compound was prepared in the same manner as in Example 1 except for the use of 4′-chloro acetophenone and 2-methoxy phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.28 (m, 2H), 2.39 (m, 2H), 3.09 (m, 4H), 3.23 (m, 4H), 3.70 (s, 3H), 4.99 (br, 2H), 5.88 (t, 1H), 7.11 (m, 4H), 7.31 (m, 4H)
A title compound was prepared in the same manner as in Example 1 except for the use of acetophenone and 4-hydroxy phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 1.99 (m, 2H), 2.14 (m, 2H), 2.58 (m, 4H), 3.12 (m, 4H), 5.12 (br, 2H), 5.78 (t, 1H), 6.99 (m, 4H), 7.21 (m, 5H)
The compound 'carbamic acid 3-[4-(4-hydroxy-phenyl)-piperazin-1-yl]-1-phenyl-propyl ester (2 mmol) prepared in Example 84 was dissolved in tetrahydrofuran (25 mL), and potassium carbonate (K2CO3, 2.4 mmol) and benzylbromide (2.4 mmol) were added thereto, and the resulting mixture was stirred at 70° C. for 10 hours. The reaction mixture was diluted with water, and extracted several times with ethyl acetate to obtain an organic phase. The prepared organic phase was dried over magnesium sulfate, and concentrated under a reduced pressure. The resulting pellet was purified with column chromatography (hexane:ethyl acetate=1:1) to obtain a title compound.
1H NMR (200 MHz, CDCl3) d: 2.05 (m, 1H), 2.17 (m, 1H), 2.37 (m, 2H), 2.65 (m, 4H), 3.14 (m, 4H), 4.65 (br, 2H), 5.04 (s, 2H), 5.87 (t, 1H), 7.29-7.43 (m, 9H)
The compound 'carbamic acid 3-[4-(4-hydroxy-phenyl)-piperazin-1-yl]-1-phenyl-propyl ester (2 mmol) prepared in Example 84 was dissolved in tetrahydrofuran (25 mL), and triethylamine (2.4 mmol) and acetylchloride (2.4 mmol) were added thereto, and the resulting mixture was stirred at a room temperature for 5 hours. The reaction mixture was diluted with water, and extracted several times with ethyl acetate to obtain an organic phase. The prepared organic phase was dried over magnesium sulfate, and concentrated under a reduced pressure. The resulting pellet was purified with column chromatography (hexane:ethyl acetate=1:1) to obtain a title compound.
1H NMR (200 MHz, CDCl3) d: 2.04 (m, 1H), 2.17 (m, 1H), 2.29 (s, 3H), 2.43 (m, 2H), 2.61 (m, 4H), 3.19 (m, 4H), 4.74 (br, 2H), 5.75 (t, 1H), 6.95 (m, 4H), 7.33 (m, 5H)
The compound 'carbamic acid 3-[4-(4-hydroxy-phenyl)-piperazin-1-yl]-1-phenyl-propyl ester (2 mmol) prepared in Example 84 was dissolved in tetrahydrofuran (25 mL), and triethylamine (2.4 mmol) and bromopentyl (2.4 mmol) were added thereto, and the resulting mixture was stirred at 80? for 10 hours. The reaction mixture was diluted with water, and extracted several times with ethyl acetate to obtain an organic phase. The prepared organic phase was dried over magnesium sulfate, and concentrated under a reduced pressure. The resulting pellet was purified with column chromatography (hexane:ethyl acetate=1:1) to obtain a title compound.
1H NMR (200 MHz, CDCl3) d: 1.61 (m, 3H), 85 (m, 8H), 2.11 (m, 1H), 2.27 (m, 1H), 2.62 (m, 4H), 3.11 (m, 4H), 4.76 (br, 2H), 5.78 (t, 1H), 6.85 (m, 4H), 7.34 (m, 5H)
A title compound was prepared in the same manner as in Example 1 except for the use of 4′-fluoro acetophenone and 4-hydroxy phenyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 1.97 (m, 1H), 2.12 (m, 1H), 2.40 (m, 2H), 2.62 (m, 4H), 3.08 (m, 4H), 4.78 (br, 2H), 5.82 (t, 1H), 7.07 (m, 5H), 7.23 (m, 3H)
The compound 'carbamic acid 1-(4-fluoro-phenyl)-3-[4-(4-hydroxy-phenyl)-piperazin-1-yl]-propyl ester (2 mmol) prepared in Example 88 was dissolved in acetone (15 mL), and triethylamine (2.4 mmol) was added and trimethyl acetylchloride (2.4 mmol) was added dropwise, and the resulting mixture was then stirred at a room temperature for 5 hours. The reaction mixture was diluted with water, and extracted several times with ethyl acetate to obtain an organic phase. The prepared organic phase was dried over magnesium sulfate, and concentrated under a reduced pressure. The resulting pellet was purified with column chromatography (hexane:ethyl acetate=1:1) to obtain a title compound.
1H NMR (200 MHz, CDCl3) d: 1.35 (m, 9H), 1.97 (m, 1H), 2.21 (m, 1H), 2.42 (m, 2H), 2.64 (m, 4H), 3.17 (m, 4H), 4.90 (br, 2H), 5.75 (t, 1H), 6.94 (m, 4H), 7.08-7038 (m, 4H)
The compound 'carbamic acid 1-(4-fluoro-phenyl)-3-[4-(4-hydroxy-phenyl)-piperazin-1-yl]-propyl ester (0.93 mmol) prepared in Example 88 was dissolved in acetone (15 mL), and triethylamine (1.86 mmol) was added and ethyl chloroformate (2.4 mmol) was added dropwise, and the resulting mixture was then stirred at a room temperature for 5 hours. The reaction mixture was diluted with water, and extracted several times with ethyl acetate to obtain an organic phase. The prepared organic phase was dried over magnesium sulfate, and concentrated under a reduced pressure. The resulting pellet was purified with column chromatography (hexane:ethyl acetate=1:1) to obtain a title compound.
1H NMR (200 MHz, CDCl3) d: 1.40 (m, 3H), 2.04 (m, 1H), 2.21 (m, 1H), 2.43 (m, 2H), 2.63 (m, 4H), 3.19 (m, 4H), 4.30 (m, 2H), 4.79 (br, 2H), 5.72 (t, 1H), 6.88 (m, 2H), 7.06 (m, 4H), 7.34 (m, 4H)
The compound 'carbamic acid 1-(4-fluoro-phenyl)-3-[4-(4-hydroxy-phenyl)-piperazin-1-yl]-propyl ester (1 mmol) prepared in Example 88 was dissolved in acetone (20 mL), and triethylamine (2 mmol) was added and benzyl chloroformate (2.4 mmol) was added dropwise, and the resulting mixture was then stirred at a room temperature for 5 hours. The reaction mixture was diluted with water, and extracted several times with ethyl acetate to obtain an organic phase. The prepared organic phase was dried over magnesium sulfate, and concentrated under a reduced pressure. The resulting pellet was purified with column chromatography (hexane:ethyl acetate=1:1) to obtain a title compound.
1H NMR (200 MHz, CDCl3) d: 1.99 (m, 2H), 2.12 (m, 2H), 2.66 (m, 4H), 3.12 (m, 4H), 3.52 (s, 2H), 4.90 (br, 2H), 5.81 (t, 1H), 6.89 (m, 4H), 7.33 (m, 9H)
The compound 'carbamic aid 1-(4-fluoro-phenyl)-3-[4-(4-hydroxy-phenyl)-piperazin-1-yl]-propyl ester (0.6 mmol) prepared in Example 88 was dissolved in acetone (15 mL), and triethylamine (1.2 mmol) was added and acetylchloride (2.4 mmol) was added dropwise, and the resulting mixture was then stirred at a room temperature for 5 hours. The reaction mixture was diluted with water, and extracted several times with ethyl acetate to obtain an organic phase. The prepared organic phase was dried over magnesium sulfate, and concentrated under a reduced pressure. The resulting pellet was purified with column chromatography (hexane:ethyl acetate=1:1) to obtain a title compound.
1H NMR (200 MHz, CDCl3) d: 2.02 (m, 1H), 2.17 (m, 1H), 2.38 (s, 3H), 2.42 (m, 2H), 2.60 (m, 4H), 3.18 (m, 4H), 4.82 (br, 2H), 5.75 (t, 1H), 6.88-7.09 (m, 6H), 7.33 (m, 2H)
3-chloro propiophenone (4 mmol) and 4,4′-bisfluorophenylpiperazine (5.2 mmol) were dissolved in acetonitrile (50 mL), and triethylamine (5.2 mmol) was added dropwise thereto, and the resulting mixture was stirred at 80° C. for 24 hours. The resulting reaction mixture was diluted with water, and extracted several times with ethylacetate. The resulting organic phase was dried over magnesium sulfate and filtered, and the resulting filtrate was concentrated under a reduced pressure, and separated and purified with column chromatography (hexane:ethylacetate=1:1). The resulting compound (3.5 mmol) was dissolved in methanol (20 mL), and cooled to 0° C., and sodium borohydride (5 mmol) was added slowly to the mixture. The resulting mixture was stirred at a room temperature for 2 hours, and concentrated under a reduced pressure, and obtained a yellow pellet. Then, the prepared yellow pellet was purified with column chromatography (hexane:ethylacetate=1:1) to obtain a crude compound.
The prepared crude compound (2 mmol) was dissolved in tetrahydrofuran (10 mL), and 1,1′-carbodiimidazole (4 mmol) was added thereto, and the resulting mixture was stirred at a room temperature for 1 hour. Then, excessive ammonium hydroxide was added to the mixture, and the resulting mixture was then stirred at a room temperature for 1 hour. The reaction mixture was diluted with water, and extracted several times with ethyl acetate to obtain an organic phase. The prepared organic phase was dried over magnesium sulfate, and concentrated under a reduced pressure. The resulting pellet was purified with column chromatography (hexane:ethyl acetate=1:1) to obtain a title compound.
1H NMR (200 MHz, Acetone) d 2.34 (m, 10H), 2.84 (m, 2H), 4.35 (s, 1H), 5.7 (t, 1H), 5.99 (br, 2H), 7.07 (m, 4H), 7.31 (m, 5H), 7.50 (m, 4H)
A title compound was prepared in the same manner as in Example 93 except for the use of 4-bromobutyrophenone and phenylpiperazine as starting materials.
1H NMR (500 MHz, DMSO) d 1.82 (m, 2H), 2.78 (m, 3H), 3.08 (m, 4H), 3.21 (m, 4H), 3.52 (m, 2H), 5.51 (br, 2H), 5.78 (t, 1H), 7.01 (m, 5H), 7.23 (m, 5H)
A title compound was prepared in the same manner as in Example 93 except for the use of 4-bromobutyrophenone and 2-methoxyphenylpiperazine as starting materials.
1H NMR (500 MHz, DMSO) d 1.88 (m, 4H), 3.10-3.30 (m, 6H), 3.52 (m, 4H), 3.80 (s, 3H), 5.42 (br, 2H), 5.51 (t, 1H), 6.91 (m, 1H), 7.01 (m, 2H), 7.09 (m, 1H), 7.33 (m, 5H)
A title compound was prepared in the same manner as in Example 93 except for the use of 4-bromobutyrophenone and 2-pyridylpiperazine as starting materials.
1H NMR (500 MHz, DMSO) d 3.12 (m, 6H), 3.44 (m, 4H), 3.64 (m, 4H), 4.52 (m, 4H), 5.55 (t, 1H), 6.51-6.91 (br, 2H), 7.01 (m, 2H), 7.30-7.40 (m, 5H), 8.01 ((m, 2H)
A title compound was prepared in the same manner as in Example 93 except for the use of 4-bromobutyrophenone and 1-(3-chloro-pyridin-2-yl)-piperazine as starting materials.
1H NMR (500 MHz, DMSO) d 1.78 (m, 5H), 3.80 (m, 3H), 3.52 (m, 3H), 3.41 (m, 3H), 5.02 (br, 2H), 5.50 (t, 1H), 7.10 (m, 1H), 7.41 (m, 5H), 7.91 (m, 1H), 8.31 ((m, 1H)
A title compound was prepared in the same manner as in Example 93 except for the use of 3-chloropropiophenone and 3,4-methylene dioxy benzylpiperazine as starting materials.
1H NMR (200 MHz, Acetone) d 1.99 (m, 2H), 2.35 (m, 10H), 3.40 (d, 2H), 5.78 (t, 1H), 5.97 (br, 4H), 6.78 (d, 2H), 6.87 (s, 1H), 7.36 (m, 5H)
A title compound was prepared in the same manner as in Example 93 except for the use of 3-chloropropiophenone and benzoyl piperazine as starting materials.
1H NMR (200 MHz, CDCl3) d 1.9-2.3 (m, 8H), 3.2-3.8 (br, 4H), 4.95 (br, 2H), 5.82 (t, 1H), 7.32-7.39 (m, 10H)
A title compound was prepared in the same manner as in Example 93 except for the use of 3-chloropropiophenone and benzyl piperazine as starting materials.
1H NMR (200 MHz, Acetone) d 2.07 (m, 2H), 2.41 (m, 10H), 3.53 (s, 2H), 4.90 (br, 2H), 5.70 (t, 1H), 7.31 (m, 10H)
(R)-3-chloro-1-phenyl-1-propanol (10 mmol) was dissolved in acetonitrile (100 ml), and 2,6-dimethyl-4-methoxy phenylpiperazine (12 mmol) and triethylamine (12 mmol) were added to the resulting mixture. The prepared mixture was stirred at 80° C. for 24 hours. The resulting reaction mixture was diluted with water, and extracted several times with ethyl acetate. The extracted organic phase was washed with an aqueous sodium chloride solution, dried over magnesium sulfate, and then concentrated under a reduced pressure to obtain a pellet. The prepared pellet (8.2 mmol) was dissolved in tetrahydrofuran (50 mL), and 1,1′-carbonyl dimidazole (16.5 mmol) was added thereto, and the resulting mixture was stirred at a room temperature for 1 hour. Excessive ammonium hydroxide was added to the mixture, and the resulting mixture was stirred for 2. The resulting reaction mixture was diluted with water, and extracted several times with ethyl acetate to obtain an organic phase. Then, the prepared organic phase was dried over magnesium sulfate, and concentrated under a reduced pressure. The resulting yellow pellet was purified with column chromatography (hexane:ethyl acetate=1:1) to obtain a title compound.
1H NMR (200 MHz, CDCl3) d 1.05 (dd, 6H), 1.99 (m, 2H), 2.45 (m, 2H), 2.78 (m, 4H), 3.27 (m, 2H), 3.78 (s, 3H), 4.71 (br, 2H), 5.66 (t, 1H), 6.85 (m, 4H), 7.3 (m, 5H)
A title compound was prepared in the same manner as in Example 101 except for the use of (R)-3-chloro-1-phenyl-1-propanol and 4-methoxyphenylpiperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.12 (m, 1H), 2.27 (m, 1H), 2.42 (m, 2H), 2.65 (m, 4H), 3.13 (m, 4H), 3.79 (s, 3H), 4.87 (br, 2H), 5.79 (t, 1H), 6.89 (m, 4H), 7.33 (m, 5H)
A title compound was prepared in the same manner as in Example 101 except for the use of (R)-3-chloro-1-phenyl-1-propanol and 4-chlorophenylpiperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 1.98 (m, 1H), 2.21 (m, 1H), 2.43 (m, 2H), 2.60 (m, 4H), 3.18 (m, 4H), 4.67 (br, 2H), 5.76 (t, 1H), 6.85 (m, 2H), 7.24 (m, 2H), 7.37 (m, 5H)
A title compound was prepared in the same manner as in Example 101 except for the use of (R)-3-chloro-1-phenyl-1-propanol and 4-fluorophenylpiperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.11 (m, 1H), 2.21 (m, 1H), 2.29 (m, 2H), 2.61 (m, 4H), 3.14 (m, 4H), 4.83 (br, 2H), 5.75 (t, 1H), 6.93 (m, 4H), 7.33 (m, 5H)
A title compound was prepared in the same manner as in Example 101 except for the use of (R)-3-chloro-1-phenyl-1-propanol and 4-hydroxyphenylpiperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 1.99 (m, 2H), 2.14 (m, 2H), 2.58 (m, 4H), 3.12 (m, 4H), 5.12 (br, 2H), 5.78 (t, 1H), 6.99 (m, 4H), 7.21 (m, 5H)
A title compound was prepared in the same manner as in Example 101 except for the use of (S)-3-chloro-1-phenyl-1-propanol and 4-methoxyphenylpiperazine as starting materials.
1H NMR (200 MHz, CDCl3) d: 2.12 (m, 1H), 2.27 (m, 1H), 2.42 (m, 2H), 2.65 (m, 4H), 3.13 (m, 4H), 3.79 (s, 3H), 4.87 (br, 2H), 5.79 (t, 1H), 6.89 (m, 4H), 7.33 (m, 5H)
2′-nitro acetophenone (4.67 mmol) and 4-methoxyphenylpiperazine (5.61 mmol) were dissolved in ethanol (30 mL), and the resulting mixture was adjusted to pH 2 to 3 by adding concentrated hydrochloric acid dropwise. Paraformaldehyde (37.36 mmol) was added to the mixture, and the resulting mixture was refluxed for 24 hours. The resulting reaction mixture were distilled under a reduced pressure, neutralized with 1 normal sodium chloride aqueous solution, diluted with water, and then extracted several times with ethylacetate. The resulting organic phase was dried over magnesium sulfate, and filtered, and the resulting filtrate was concentrated under a reduced pressure, and separated and purified with column chromatography (hexane:ethyl acetate=1:1) to obtain a crude compound. The separated crude compound (3.65 mmol) was dissolved in methanol (30 mL), and cooled to 0° C., and sodium borohydride (NaBH4, 7 mmol) was added slowly to the mixture. The resulting mixture was stirred at a room temperature for 2 hours, and concentrated under a reduced pressure. Then, the resulting orange pellet was purified with column chromatography (hexane:ethylacetate=1:1). The purified compound (3.1 mmol) was dissolved in methanol, and subject to the hydrogenation reaction at the presence of platinum catalyst to obtain an amino compound with a reduced nitro group. The prepared compound (1.21 mmol) was dissolved in tetrahydrofuran (20 mL), and triethylamine (3 mmol) was added, and phosgene (a 2.4 M toluene solution, 1.21 mmol) was added slowly to the mixture. In this case, a temperature of the reaction product was carefully maintained in a temperature range of no more than 10° C. The reaction product was stirred at a room temperature for 16 hours, diluted with ammonium hydroxide, and then extracted several times with ethyl acetate. The resulting organic phase was dried over magnesium sulfate, and filtered, and the resulting filtrate was concentrated under a reduced pressure, and re-crystallized from ethyl acetate to prepare a final compound.
1H NMR (200 MHz, CDCl3) d 2.07 (m, 4H), 2.61 (m, 4H), 3.12 (m, 4H), 3.78 (s, 3H), 5.58 (t, 1H), 6.85 (m, 5H), 7.16 (m, 1H), 7.22 (m, 3H), 9.14 (s, 1H)
Phenyl-1-propenyl-ketone (4.1 mmol) and 4-methoxy phenylpiperazine (4.9 mmol) were dissolved in ethanol (30 mL), and the resulting mixture was stirred at 72° C. for 48 hours. The mixture was distilled under a reduced pressure, diluted with water, and then extracted twice with ethyl acetate. The resulting organic phase was distilled under a reduced pressure, dried over magnesium sulfate, and filtered, and the resulting filtrate was concentrated under a reduced pressure, and purified with column chromatography (hexane:ethylacetate=4:1) to obtain a crude compound. The prepared crude compound (2.9 mmol) was dissolved in methanol (20 mL), and NaBH4 (3.8 mmol) was added slowly to the mixture. The resulting mixture was stirred at a room temperature for 2 hour, and concentrated under a reduced pressure, and obtained a yellow pellet. The prepared yellow pellet was purified with column chromatography (hexane:ethylacetate=1:1). The purified compound (2 mmol) was dissolved in tetrahydrofuran (15 mL), and 1,1′-carbodiimidazole (4 mmol) was added to the purified compound. The resulting mixture was stirred at a room temperature for 1 hour, and excessive ammonium hydroxide was added to the mixture, and the resulting mixture was stirred at a room temperature for additional 2 hours. The resulting reaction mixture was diluted with water, and extracted several times with ethyl acetate to obtain an organic phase. The prepared organic phase was dried over magnesium sulfate, and concentrated under a reduced pressure. The resulting pellet was purified with column chromatography (hexane:ethyl acetate=1:1) to obtain a final compound.
1H NMR (200 MHz, CDCl3) d 1.81 (m, 1H), 2.32 (m, 1H), 2.5 (m, 3H), 2.8 (m, 2H), 3.14 (m, 4H), 3.80 (s, 3H), 4.80 (br, 2H), 6.02 (t, 1H), 6.92 (m, 4H), 7.36 (m, 5H)
A title compound was prepared in the same manner as in Example 104 except for the use of phenyl-1-propenyl-ketone and 4-chlorophenylpiperazine as starting materials.
1H NMR (200 MHz, CDCl3) d 1.82 (m, 2H), 2.31 (m, 1H), 2.74-2.55 (m, 8H), 3.18 (m, 3H), 4.69 (br, 2H), 5.90 (t, 1H), 6.87 (m, 2H), 7.22 (m, 2H), 7.32 (m, 5H)
A title compound was prepared in the same manner as in Example 104 except for the use of phenyl-1-propenyl-ketone and 4-nitrophenylpiperazine as starting materials.
1H NMR (200 MHz, CDCl3) d 1.81 (m, 2H), 1.91 (m, 1H), 2.20-2.90 (m, 8H), 3.45 (m, 3H), 4.75 (br, 2H), 5.92 (t, 1H), 6.84 (m, 2H), 7.35 (m, 5H), 8.13 (m, 2H)
A title compound was prepared in the same manner as in Example 104 except for the use of phenyl-1-propenyl-ketone and 3,4-dimethylphenylpiperazine as starting materials.
1H NMR (200 MHz, CDCl3) d 1.72 (m, 2H), 2.20 (s, 3H), 2.52 (s, 3H), 2.52 (m, 4H), 2.80 (m, 3H), 3.17 (m, 5H), 5.01 (br, 2H), 5.82 (t, 1H), 6.90 (m, 2H), 7.05 (m, 1H), 7.37 (m, 5H)
A title compound was prepared in the same manner as in Example 104 except for the use of phenyl-1-propenyl-ketone and 2-piperazin-1-yl-quinoxaline as starting materials.
1H NMR (200 MHz, CDCl3) d 1.71 (m, 2H), 2.21 (m, 2H), 2.48-2.78 (m, 7H), 3.83 (m, 3H), 4.69 (br, 2H), 5.87 (t, 1H), 7.38 (m, 5H), 7.61 (m, 3H), 7.86 (m, 1H), 8.59 (d, 1H)
A title compound was prepared in the same manner as in Example 104 except for the use of phenyl-1-propenyl-ketone and 3,4-dimethoxyphenylpiperazine as starting materials.
1H NMR (200 MHz, CDCl3) d 1.32 (m, 1H), 2.21 (m, 1H), 2.42 (m, 4H), 2.72 (m, 4H), 3.10 (m, 5H), 3.80 (s, 3H), 3.83 (s, 3H), 5.01 (br, 2H), 5.89 (t, 1H), 6.42 (d, 1H), 6.80 (d, 1H), 6.89 (d, 1H), 7.33 (m, 5H)
A title compound was prepared in the same manner as in Example 104 except for the use of phenyl-1-propenyl-ketone and 3,5-dichloropyridylpiperazine as starting materials.
1H NMR (200 MHz, CDCl3) d 1.68 (m, 1H) 2.21 (m, 2H), 2.54 (m, 4H), 2.71 (m, 2H), 3.36 (m, 5H), 5.01 (br, 2H), 5.91 (t, 1H), 7.2-7.4 (m, 5H), 7.60 (m, 1H), 8.10 (m, 1H)
A title compound was prepared in the same manner as in Example 104 except for the use of phenyl-1-propenyl-ketone and 3,4-dichlorophenylpiperazine as starting materials.
1H NMR (200 MHz, CDCl3) d 1.62 (m, 2H), 1.96 (m, 2H), 2.20-2.60 (m, 5H), 2.75 (m, 2H), 3.16 (m, 3H), 4.96 (br, 2H), 5.91 (t, 1H), 6.77 (m, 1H), 7.00 (m, 1H), 7.36 (m, 6H)
A title compound was prepared in the same manner as in Example 104 except for the use of phenyl-1-propenyl-ketone and 2,4-difluorophenylpiperazine as starting materials.
1H NMR (200 MHz, CDCl3) 1.86 (m, 2H), 2.12 (m, 2H), 2.52 (m, 4H), 2.75 (m, 3H), 3.06 (m, 3H), 4.98 (br, 2H), 5.81 (t, 1H), 6.79 (m, 3H), 7.36 (m, 5H)
3-chloropropiophenone (14.77 mmol) and phenylpiperazine (17.7 mmol) were dissolved in acetonitrile (50 mL), and triethylamine (17.7 mmol) was added thereto, and the resulting mixture was stirred at 80° C. for 24 hours. The resulting reaction mixture was diluted with water, and extracted several times with ethyl acetate. The extracted organic phase was collected, washed with water and an aqueous saturated sodium chloride solution, dried over magnesium sulfate, and then concentrated under a reduced pressure to obtain a pellet. The prepared pellet (1.75 mmol) was dissolved in tetrahydrofuran (20 mL), and 1.5 mole of a cyclohexanelithium diimide (1.92 mmol) solution was added dropwise while the resulting mixture was maintained to a temperature of −78° C. Then, the resulting mixture was stirred at −78° C. for 10 minutes, and then stirred at 0° C. for 30 minutes. After the resulting mixture was cooled again and maintained to a temperature of −78° C., N-fluorobenzenesulfonimide (2.27 mmol) was added to the mixture, and the resulting mixture was stirred at a room temperature for 2 hours. The resulting reaction mixture was diluted by adding a saturated ammonium chloride solution, and the diluted reaction mixture was extracted several times with ethylacetate. The resulting organic phase was dried over magnesium sulfate, and concentrated under a reduced pressure. In this case, the resulting pellet was purified with column chromatography (hexane:ethyl acetate=1:4) to obtain a crude compound. The prepared crude compound (1.5 mmol) was dissolved in methanol (20 mL), and NaBH4 (3.0 mmol) was added slowly to the mixture. The resulting mixture was stirred at a room temperature for 1 hour, and concentrated under a reduced pressure to remove off solvents. The resulting pellet was then purified with column chromatography (hexane:ethylacetate=1:2) to obtain a crude compound. The prepared crude compound (1 mmol) was dissolved in tetrahydrofuran (20 mL), and 1,1′-carbodiimidazole (2 mmol) was added thereto, and the resulting mixture was stirred at a room temperature for 2 hour. Then, excessive ammonium hydroxide was added to the mixture, and the resulting mixture was stirred at a room temperature for additional 2 hours. The resulting reaction mixture was diluted with water, and extracted several times with ethyl acetate to obtain an organic phase. The prepared organic phase was dried over magnesium sulfate, and then concentrated under a reduced pressure. The resulting pellet was purified with column chromatography (hexane:ethyl acetate=1:4) to obtain a final compound.
1H NMR (200 MHz, CDCl3) d 2.59 (m, 6H), 3.19 (m, 4H), 4.92 (m, 1H, J=48 Hz), 5.52 (br, 2H), 5.92 (m, 1H, J=18 Hz), 6.90 (m, 3H), 7.34 (m, 7H)
The compounds as listed above were tested for analgesic effects using the following animal models.
2. Acetic Acid-Induced Writhing Test in Mouse
An acetic acid-induced writhing test is one of models for measuring an analgesic effect of drugs. A test material dissolved in a suitable vehicle was orally administered to a male ICR mouse weighing 30 to 35 g at an amount of 10 mg/kg. After 1 hour of the oral administration, 10 mg/ml of an aqueous 0.8% acetic acid solution was intraperitoneally injected into the male ICR mouse to induce the abdominal pain of the male ICR mouse. Right after the administration of acetic acid, the male ICR mouse was put into an empty cage, and the number of writhing behaviors of the mice was counted for 10 minutes. The term “writhing represents a reflex action in which the mouse overtly extends its abdomen by stretching its hind legs due to the abdominal pain. The analgesic effect of the test material is represented by the ‘suppression ratio of pain response’ {[(Writhing number of Vehicle-administered group−Writhing number of Test material-administered group)/(Writhing number of Vehicle-administered group)]×100%} or 50% of Effective amount (ED50 (median effective dose); an amount of test material that is required to suppress 50% of pain behaviors) of Test material. The ED50 (median effective dose) was determined by calculating the suppression ratio of pain response in at least three doses of test materials and subjecting to the linear regression. From these results, it was observed that the higher analgesic effect shows the higher suppression ratio of pain response (%), but the lower ED50 value.
3. Formalin Test—Late Phase in Mouse
A formalin test is another model for measuring an analgesic effect of drugs. When a formalin solution was subcutaneously administered into the planta surface of a mouse's hindlimb, the mouse shows specific pain behaviors such as immediately holding up and down, flinching and licking a mouse's left foot. These pain behaviors have a biphasic pattern, and therefore they are divided into an early-phase behavior within 10 seconds after the formalin administration; and a late-phase behavior up to 10 to 60 minutes. The medicinal effect observed in the formalin test-late phase means an analgesic effect of the test material in the inflammatory pain model, and also becomes a measure that may predict the medicinal effects in the neuropathic pain model (Vissers K et. al, 2003). A test material was orally administered to a male ICR mouse weighing 30 to 35 g. After 1 hour of the oral administration, 20 μl of a 2.5% formalin solution was subcutaneously injected into the planta surface of a mouse's hindlimb to induce pain. After 20 minutes of the administration of the formalin solution, the time when the mouse shows the pain behaviors (flinching, licking, etc.) was recorded for 15 minutes, and quantified. The analgesic effect of the test material is represented by the ‘suppression ratio of pain response’ {[(Pain response time of Vehicle-administered group−Pain response time of Test material-administered group)/(Pain response time of Vehicle-administered group)]×100%}, or ‘50% of Effective amount (ED50; an amount of a test material that is required to suppress 50% of pain behaviors) of Test material’. The ED50 (median effective dose) was determined by calculating the suppression ratio of pain response in at least three doses of test materials and subjecting to the linear regression. From these results, it was observed that the higher analgesic effect shows the higher suppression ratio of pain response (%), but the lower ED50 value.
It has been known that the actions of serotonin (5-HT) receptors are closely related to the induction of various psychiatry disorders, for example, depression, anxiety, schizophrenia, phobia, obsession, migraine headache, panic disorder, etc. The serotonin receptor is divided into subtypes including 5-HT1, 5-HT2, 5HT3, 5-HT4, 5-HT6, 5-HT7, etc. In particular, the 5-HT1 receptor is divided into subtypes: 5-HT1A, 5-HT1B, 5-HT1E, 5-HT1F etc. From the preclinical electrophysiologic test, it was found that the 5-HT1A receptor of postsynaptic neuron is associated with the anti-depression effect. Also, it was found that stimulation of the 5-HT1A receptor of the postsynaptic increases the anxiety, and activation of the 5-HT1A receptor of presynaptic reduces the anxiety. The 5-HT2A receptor tends to sharply decrease from adolescence to middle age of a normal human, and to slowly decrease after the middle age. A level of the 5-HT2A receptor in an elderly patient suffering from depression is very lower than that of the normal human, and therefore it was found that the deficiency of serotonin in a wide region of brain may be one cause of the depression in the elderly. The above-mentioned compounds were tested for medicinal effects against depression and anxiety through their binding to the 5-HT1A receptor and the 5-HT2A receptor.
Binding to 5-HT1A Receptor
10 6-week-old Sprague-Dawley (SD) rats were anesthetized in an ether container for minutes, brains were separated from rats, and cortical regions were then separated from the brains of the rats. The cortical regions of the rats were put into a Tris-HCl buffer solution (50 mM, pH 7.4) and homogenized, and the homogenate was centrifuged twice at 4? at a rotary speed of 50,000 g to obtain a precipitate (membrane protein). The precipitate was put into a buffer solution, and homogenized, which was used later as a protein source. 2 nM [3H]-8-OH-DPAT was used as a radioactive isotope, and 10 uM serotonin was used to remove non-specific bindings. 25 ul of the compound, 100 ul of an aqueous radioactive isotope solution, and 100 ul of the protein source were put together, and kept at 25° C. for 1 hour. The resulting mixture was filtered with a membrane filter in a 96-well harvester when the 96-well plate reaction was completed. The competitivity of the compound to [3H]-8-OH-DPAT was determined by taking the membrane filter and measuring the radioactivity of the membrane filter in a scintillation counter, and an IC50 value was determined by measuring the increasing concentration of the compound. The specific reaction of the compound accounted for 90% or more. The general experiments were carried out according to the method by Middlemiss et al. (1984, Eur. J. Pharmacol.).
Binding to 5-HT2A Receptor
10 6-week-old Sprague-Dawley (SD) rats were anesthetized in an ether container for 5 minutes, brains were separated from rats, and cortical regions were then separated from the brains of the rats. The cortical regions of the rats were put into a Tris-HCl buffer solution (50 mM, pH 7.7) and homogenized, and the homogenate was centrifuged twice at 4° C. at a rotary speed of 50,000 g to obtain a precipitate (membrane protein). The precipitate was put into a buffer solution, and homogenized, which was used later as a protein source. 0.5 nM [3H]-Ketanserin was used as a radioactive isotope, and 10 uM serotonin was used to remove non-specific bindings. 25 ul of the compound, 100 ul of an aqueous radioactive isotope solution, and 100 ul of the protein source were put together, and kept at 25° C. for 1 hour. The resulting mixture was filtered with a membrane filter in a 96-well harvester when the 96-well plate reaction was completed. The competitivity of the compound to [3H]-Ketanserin was determined by taking the membrane filter and measuring the radioactivity in a scintillation counter, and an IC50 value was determined by measuring the increasing concentration of the compound. The specific reaction of the compound accounted for 90% or more. The general experiments were carried out according to the method by Leysen et al. (1982, Eur. J. Pharmacol).
For the use in treating various diseases such as a wide range of pains (including acute pain, chronic pain, neuropathic pain, post-surgery neuropathic pain, diabetic neuropathic pain, postherpetic neuralgia, inflammatory pain, joint pain, migraine headache and the like, anxiety and depression), anxiety and depression, the compound of the present invention is administered to patient, alone or in combinations with pharmaceutically available carriers. An exact dose of the administered compound may be determined according to the conditions of patients, the severity of patient status and the activity of the compound. Under the specific circumstances, the optimum dose of the administered compound should essentially be determined in a clinical manner, but be present within the scope of the present invention.
For the use of the compound according to the present invention, the compound is preferably administered orally since the compound is easily absorbed orally, but the present invention is not particularly limited thereto. For the oral administration, the compound represented by Formula 1 is preferably used in combinations with a pharmaceutical carrier. A dose ratio of the carrier to the inventive compound is limited to allow the compound to take an effect on patients, and may be widely varied, depending on whether the composition is filled into a capsule, or formulated into a tablet. In the case of the tablet, edible and pharmaceutical carriers or mixtures thereof may be used herein. Examples of the suitable carriers includes, but are not particularly limited to, lactose, dibasic calcium phosphate and/or corn starch, and mixtures thereof, etc. Other pharmaceutically available compounds may be further added, including a lubricant such as magnesium stearate.
| Number | Date | Country | Kind |
|---|---|---|---|
| 10-2007-0046708 | May 2007 | KR | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/KR2008/002466 | 4/30/2008 | WO | 2/23/2011 |
| Number | Date | Country | |
|---|---|---|---|
| 20100160331 A1 | Jun 2010 | US |
